PAREXEL International has expanded its services and capabilities for genomic-based drug development. The PAREXEL Genomic Medicine team now offers a variety of strategic and operational genomic research services aimed at accelerating drug development and to support regulatory and payer approval processes.
 
Increasingly, biopharma companies are applying genomics to drug discovery and development in an effort to better understand the genetic basis of disease, and regulators and payers are increasingly seeking genomic information to make more informed decisions.
 
“Recently, the terms ‘precision medicine’ and ‘personalized medicine’ have become household terms, and genomic research is the key to developing targeted therapies. By applying innovative and state-of-the-art methodologies, we work with our clients to understand how genes impact an individual’s response to treatment – and why people who receive the same treatment may respond differently,” said Sy Pretorius, M.D., chief scientific officer, PAREXEL. “PAREXEL’s Genomic Medicine team leverages genomic information across more than 10 therapeutic areas to help biopharmaceutical companies discover, develop, and secure regulatory and payer approval for their new medicines.”
 
PAREXEL’s Genomic Medicine team is comprised of more than 15 scientists with experience in genomics, drug discovery, and drug development. The team joined PAREXEL from GlaxoSmithKline’s Genetics and Computational Biology departments.